Comparative Effectiveness and Safety of Rituximab Versus Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: A Finnish Population-Based Matched Cohort Study - PubMed
3 days ago
- #ocrelizumab
- #rituximab
- #multiple sclerosis
- The study compared rituximab (RTX) and ocrelizumab (OCR) for relapsing-remitting multiple sclerosis (RRMS) in a Finnish real-world cohort, finding similar effectiveness.
- Both treatments showed low and comparable annualized relapse rates (mean 0.03) and no difference in relapse-free survival or MRI activity.
- Adverse events were infrequent and mild, with modest declines in IgG levels (mean -13%) in both groups, not linked to increased infections.
- No disease reactivation occurred when patients switched from OCR to RTX, supporting RTX as a viable alternative to OCR in clinical practice.